NCT06952855已完成不适用
Observational Study to Evaluate Effectiveness, Safety and Satisfaction Level of Zastaprazan (JAQBO®) Under Daily Treatment for Patients With Erosive Gastroesophageal Reflux Disease
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 5,536
- 试验地点
- 1
- 主要终点
- Change in GERD (heartburn, acid regurgitation) score in RDQ
研究概览
简要总结
This observational study is a prospective, multi-institutional non intervention study to examine the prescription patterns, corresponding treatment effects and safety in routine clinical practice for patients prescribed for the treatment of gastroesophageal reflux disease.
详细描述
The present observational study is designed to check effect and safety for patients who have been prescribed JAQBO for the treatment of erosive gastroesophageal reflux disease.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Prospective
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •An adult over 19 years of age
- •A person who voluntarily provides written informed consent
排除标准
- •A pregnant woman or a nursing woman
- •A person who is deemed unsuitable for the subject of the study
结局指标
主要结局
Change in GERD (heartburn, acid regurgitation) score in RDQ
时间窗: 4 weeks
Scale(none / 1day / 2day/ 3-4 day / 5-6 day/ every day)
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Observational Study of Vismodegib (Erivedge) in Patients Treated in ArgentinaBasal Cell CarcinomaNCT02438644Hoffmann-La Roche75
已完成
不适用
Observational Study of Tildrakizumab in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical PracticePlaque PsoriasisNCT04203693Almirall, S.A.331
招募中
不适用
Evaluation of Enavogliflozin's Efficacy and Safety in Type II Diabetes With Hypertension or DyslipidemiaDiabetes Mellitus, Type 2NCT06647888Daewoong Pharmaceutical Co. LTD.12,000
Unknown
不适用
Efficacy and Safety of Favipiravir in the Treatment of COVID-19 Patients Over 15 Years of AgeCOVID-19NCT04474457Ministry of Health, Turkey1,000
已完成
不适用
Observational Study to Evaluate the Efficacy and Safety of TeneligliptinType 2 Diabetes MellitusNCT03793023Handok Inc.2,983